FDA today approved Celltrion’s Inflectra, a biosimilar to Janssen’s Remicade (infliximab). This is the second biosimilar to be approved by FDA under the new BPCIA regime.
For more information, see FDA’s press release on the approval, here: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm.